Safety and efficacy of mepolizumab in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis
{{output}}
Introduction: Up to 40% of patients with COPD have an eosinophilic phenotype, which increases the risk of acute exacerbations. Mepolizumab, an anti - IL-5 monoclonal antibody, has shown mixed results. We conducted a systematic re... ...
